Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration

Patel, Aateka, Woods, A., Riffo-Vasquez, Yanira, Babin-Morgan, Anna, Jones, Marie-Christine, Jones, Stuart, Sunassee, Kavitha, Clark, Stephen, T. M. de Rosales, Rafael, Page, Clive, Spina, Domenico, Forbes, Ben and Dailey, Lea Ann (2016) Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration. Journal of Controlled Release, 235, pp. 24-33. ISSN (print) 0168-3659

Full text available as:
[img]
Preview
Text
Babin-Morgan-A-39884-AAM.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Lipid nanocapsules (LNCs) are semi-rigid spherical capsules with a triglyceride core that present a promising formulation option for the pulmonary delivery of drugs with poor aqueous solubility. Whilst the biodistribution of LNCs of different size has been studied following intravenous administration, the fate of LNCs following pulmonary delivery has not been reported. We investigated quantitatively whether lung inflammation affects the clearance of 50nm lipid nanocapsules, or is exacerbated by their pulmonary administration. Studies were conducted in mice with lipopolysaccharide-induced lung inflammation compared to healthy controls. Particle deposition and nanocapsule clearance kinetics were measured by single photon emission computed tomography/computed tomography (SPECT/CT) imaging over 48 h. A significantly lower lung dose of (111)In-LNC50 was achieved in the lipopolysaccharide (LPS)-treated animals compared with healthy controls (p<0.001). When normalised to the delivered lung dose, the clearance kinetics of (111)In-LNC50 from the lungs fit a first order model with an elimination half-life of 10.5±0.9h (R(2)=0.995) and 10.6±0.3h (R(2)=1.000) for healthy and inflamed lungs respectively (n=3). In contrast, (111)In-diethylene triamine pentaacetic acid (DTPA), a small hydrophilic molecule, was cleared rapidly from the lungs with the majority of the dose absorbed within 20min of administration. Biodistribution to lungs, stomach-intestine, liver, trachea-throat and blood at the end of the imaging period was unaltered by lung inflammation. This study demonstrated that lung clearance and whole body distribution of lipid nanocapsules were unaffected by the presence of acute lung inflammation.

Item Type: Article
Additional Information: This work was supported by the Medical Research Council [grant number: G0900953].
Research Area: Biological sciences
Pharmacy
Pre-clinical and human biological sciences
Faculty, School or Research Centre: Faculty of Science, Engineering and Computing (until 2017) > School of Pharmacy and Chemistry
Related URLs:
Depositing User: Anna Morgan
Date Deposited: 09 Nov 2017 14:01
Last Modified: 16 Feb 2018 14:57
DOI: https://doi.org/10.1016/j.jconrel.2016.05.024
URI: http://eprints.kingston.ac.uk/id/eprint/39884

Actions (Repository Editors)

Item Control Page Item Control Page